Implementation and operational feasibility of SAMBA I HIV-1 semi-quantitative viral load testing at the point of care in rural settings in Malawi and Uganda.

Auteurs: Gueguen M Nicholas S Poulet E Schramm B Szumilin E Wolters L Wapling J Ajule E Rakesh A Mwenda R Kiyaga C Balkan S
Référence de l'article: Tropical medicine & international health : TM & IH 2020 Nov 07; (); Array. doi: 10.1111/tmi.13519. Epub 2020 11 07
Malawi POC testing SAMBA I Uganda descriptive analysis
eng

Abstract

OBJECTIVE: We monitored a large-scale implementation of the Simple Amplification-Based Assay semi-quantitative viral load test for HIV-1 version I (SAMBA I Viral Load = SAMBA I VL) within Médecins Sans Frontières' HIV programmes in Malawi and Uganda, to assess its performance and operational feasibility.

METHODS: Descriptive analysis of routine programme data between August 2013 and December 2016. The dataset included samples collected for VL monitoring, and tested using SAMBA I VL in five HIV clinics in Malawi (four peripheral health centres and one district hospital), and one HIV clinic in a regional referral hospital in Uganda. SAMBA I VL was used for VL testing in patients who had been receiving ART for between 6 months and ten years, to determine whether plasma VL was above or below 1000 copies/mL of HIV-1, reflecting ART failure or efficacy. Randomly selected samples were quantified with commercial VL assays. SAMBA I instruments and test performance, site throughput, and delays in communicating results to clinicians and patients were monitored.

RESULTS: Between August 2013 and December 2016 a total of 60,889 patient samples were analysed with SAMBA I VL. Overall, 0.23% of initial SAMBA I VL results were invalid; this was reduced to 0.04% after repeating the test once. Global test failure, including instrument failure, was 1.34%. Concordance with reference quantitative testing of VL was 2620/2727, 96.0% (1338/1382, 96.8% in Malawi; 1282/1345, 95.3% in Uganda). For Chiradzulu peripheral health centres and Arua Hospital HIV clinic, where testing was performed on-site, same-day results were communicated to clinicians for between 91% and 97% of samples. Same-day clinical review was obtained for 84.7% across the whole set of samples tested.

CONCLUSIONS: SAMBA I VL testing is feasible for monitoring cohorts of 1,000 to 5,000 ART-experienced patients. Same-day results can be used to inform rapid clinical decision-making at rural and remote health facilities, potentially reducing time available for development of resistance and conceivably helping to reduce morbidity and mortality.

This article is protected by copyright. All rights reserved.